PL356044A1 - Antagoniści receptora adenozyny i sposoby ich wytwarzania i zastosowania - Google Patents

Antagoniści receptora adenozyny i sposoby ich wytwarzania i zastosowania

Info

Publication number
PL356044A1
PL356044A1 PL00356044A PL35604400A PL356044A1 PL 356044 A1 PL356044 A1 PL 356044A1 PL 00356044 A PL00356044 A PL 00356044A PL 35604400 A PL35604400 A PL 35604400A PL 356044 A1 PL356044 A1 PL 356044A1
Authority
PL
Poland
Prior art keywords
making
methods
same
receptor antagonists
adenosine receptor
Prior art date
Application number
PL00356044A
Other languages
English (en)
Other versions
PL198156B1 (pl
Inventor
James E. Dowling
Carol L. Ensinger
Gnanasambandam Kumaravel
Russell C. Petter
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of PL356044A1 publication Critical patent/PL356044A1/pl
Publication of PL198156B1 publication Critical patent/PL198156B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL356044A 1999-11-12 2000-11-13 Ksantyny podstawione w pozycji 8, sposób ich wytwarzania i ich zastosowanie oraz kompozycja farmaceutyczna PL198156B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16528399P 1999-11-12 1999-11-12
PCT/US2000/031100 WO2001034604A2 (en) 1999-11-12 2000-11-13 Adenosine receptor antagonists and methods of making and using the same

Publications (2)

Publication Number Publication Date
PL356044A1 true PL356044A1 (pl) 2004-06-14
PL198156B1 PL198156B1 (pl) 2008-05-30

Family

ID=22598257

Family Applications (1)

Application Number Title Priority Date Filing Date
PL356044A PL198156B1 (pl) 1999-11-12 2000-11-13 Ksantyny podstawione w pozycji 8, sposób ich wytwarzania i ich zastosowanie oraz kompozycja farmaceutyczna

Country Status (33)

Country Link
US (4) US6605600B1 (pl)
EP (2) EP1775297A3 (pl)
JP (1) JP2003513976A (pl)
KR (1) KR100845488B1 (pl)
CN (1) CN1187354C (pl)
AT (1) ATE353328T1 (pl)
AU (1) AU784528B2 (pl)
BG (1) BG106693A (pl)
BR (1) BR0015540A (pl)
CA (1) CA2390590C (pl)
CY (1) CY1106560T1 (pl)
CZ (1) CZ20021615A3 (pl)
DE (1) DE60033310T2 (pl)
DK (1) DK1230241T3 (pl)
EA (1) EA010260B1 (pl)
EE (1) EE200200248A (pl)
ES (1) ES2281367T3 (pl)
GE (1) GEP20043267B (pl)
HK (1) HK1049153B (pl)
HU (1) HUP0203371A3 (pl)
IL (1) IL149486A0 (pl)
IS (1) IS6380A (pl)
MX (1) MXPA02004795A (pl)
NO (1) NO20022237L (pl)
NZ (2) NZ519427A (pl)
PL (1) PL198156B1 (pl)
PT (1) PT1230241E (pl)
SK (1) SK6622002A3 (pl)
TR (1) TR200301062T2 (pl)
UA (1) UA77937C2 (pl)
WO (1) WO2001034604A2 (pl)
YU (1) YU33702A (pl)
ZA (1) ZA200203702B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
CA2390496A1 (en) * 1999-11-12 2001-05-17 Biogen, Inc. Polycycloalkylpurines as adenosine receptor antagonists
PL198156B1 (pl) * 1999-11-12 2008-05-30 Biogen Idec Ma Ksantyny podstawione w pozycji 8, sposób ich wytwarzania i ich zastosowanie oraz kompozycja farmaceutyczna
RS107404A (sr) * 2002-06-12 2007-02-05 Biogen Idec Ma Inc., Metod lečenja ishemične povrede izazvane poremećajem perfuzije upotrebom antagonista adenozinskog receptora
WO2004009594A2 (en) * 2002-07-19 2004-01-29 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
MXPA05011070A (es) * 2003-04-14 2005-12-12 Pfizer Prod Inc Derivados de 3-azabiciclo [3.2.1] octano.
AU2004233852A1 (en) 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
US7247639B2 (en) * 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
JP2009528389A (ja) * 2006-03-02 2009-08-06 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシン受容体拮抗剤
CA2648281A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine a1 receptor antagonists and anticonvulsants
RS52062B (sr) 2006-05-19 2012-06-30 Abbott Laboratories Cns aktivni azabiciklični alkanski derivati koji su supstituisani spojenim bicikloheterociklom
EP2035009A1 (en) * 2006-06-16 2009-03-18 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US20090228097A1 (en) * 2008-03-07 2009-09-10 Abbott Cardiovascular Systems Inc. A1 Adenosine Receptor Antagonist-Coated Implantable Medical Device
CN114790164B (zh) 2021-08-13 2022-12-27 苏州璞正医药有限公司 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155664A (en) * 1959-11-13 1964-11-03 Endo Lab Derivatives of theophylline
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
JPH06102662B2 (ja) 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
JP2988711B2 (ja) 1989-10-20 1999-12-13 協和醗酵工業株式会社 縮合プリン誘導体
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
ATE180482T1 (de) 1991-11-08 1999-06-15 Kyowa Hakko Kogyo Kk Xanthinderivate zur behandlung der demenz
US5336769A (en) 1992-02-17 1994-08-09 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5342841A (en) 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
TW252044B (pl) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
WO1994016702A1 (fr) 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'elimination irreguliere des matieres fecales
US5395836A (en) 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
JP3729874B2 (ja) * 1993-04-07 2005-12-21 協和醗酵工業株式会社 キサンチン誘導体
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1998057645A1 (en) 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Hepatic edema remedy
WO1998057644A1 (en) 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Preventive and remedy for drug-induced nephropathy
DE19816857A1 (de) 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
WO2000001388A1 (en) 1998-07-02 2000-01-13 Kyowa Hakko Kogyo Co., Ltd. Remedies for diabetes
CA2390496A1 (en) * 1999-11-12 2001-05-17 Biogen, Inc. Polycycloalkylpurines as adenosine receptor antagonists
PL198156B1 (pl) * 1999-11-12 2008-05-30 Biogen Idec Ma Ksantyny podstawione w pozycji 8, sposób ich wytwarzania i ich zastosowanie oraz kompozycja farmaceutyczna

Also Published As

Publication number Publication date
UA77937C2 (en) 2007-02-15
HK1049153B (en) 2007-09-28
HUP0203371A3 (en) 2005-02-28
EP1775297A3 (en) 2008-12-03
KR100845488B1 (ko) 2008-07-10
US20080004293A1 (en) 2008-01-03
GEP20043267B (en) 2004-06-25
WO2001034604A2 (en) 2001-05-17
PL198156B1 (pl) 2008-05-30
NO20022237L (no) 2002-07-12
AU784528B2 (en) 2006-04-27
HK1049153A1 (en) 2003-05-02
CN1399636A (zh) 2003-02-26
AU2042101A (en) 2001-06-06
US20030225038A1 (en) 2003-12-04
MXPA02004795A (es) 2005-07-01
NZ527918A (en) 2005-05-27
HUP0203371A2 (hu) 2003-02-28
US20050222179A1 (en) 2005-10-06
IS6380A (is) 2002-05-10
BG106693A (bg) 2003-01-31
EA010260B1 (ru) 2008-06-30
EP1775297A2 (en) 2007-04-18
ZA200203702B (en) 2003-10-29
NO20022237D0 (no) 2002-05-10
TR200301062T2 (tr) 2003-09-22
KR20020049043A (ko) 2002-06-24
YU33702A (sh) 2005-03-15
ATE353328T1 (de) 2007-02-15
DE60033310T2 (de) 2007-11-22
EP1230241A2 (en) 2002-08-14
PT1230241E (pt) 2007-05-31
IL149486A0 (en) 2002-11-10
CN1187354C (zh) 2005-02-02
DK1230241T3 (da) 2007-06-04
CZ20021615A3 (cs) 2002-08-14
BR0015540A (pt) 2002-07-23
NZ519427A (en) 2003-08-29
EP1230241B1 (en) 2007-02-07
CA2390590C (en) 2010-03-16
EA200200562A1 (ru) 2002-10-31
JP2003513976A (ja) 2003-04-15
EE200200248A (et) 2003-06-16
SK6622002A3 (en) 2003-02-04
CA2390590A1 (en) 2001-05-17
US6605600B1 (en) 2003-08-12
WO2001034604A3 (en) 2002-01-10
DE60033310D1 (de) 2007-03-22
CY1106560T1 (el) 2012-01-25
ES2281367T3 (es) 2007-10-01

Similar Documents

Publication Publication Date Title
ZA200203701B (en) Polycycloalkylpurines as adenosine receptor antagonists.
ZA200203702B (en) Adenosine receptor antagonists and methods of making and using the same.
IL146871A0 (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
NZ329627A (en) 8-Heterocyclically substituted 1,3,8-triaza-spiro[4.5]decan-4-ones
PL353854A1 (pl) Podstawione pochodne 1,5-dihydropirol-2-onu, skutePodstawione pochodne 1,5-dihydropirol-2-onu, skuteczne jako substancje antagonistyczne wobec receptoczne jako substancje antagonistyczne wobec receptora-NMDA w leczeniu stanów bólowychra-NMDA w leczeniu stanów bólowych
HUT61022A (en) Process for producing 8-substituted purine derivatives functioning as selective adenosine receptor, as well as pharmaceutical compositions comprising same as active ingredient
CA2094702A1 (en) Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
GB9815618D0 (en) Treatment of dyskinesia
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
IL136949A0 (en) 1,4-diazacycloheptane derivatives for the treatment of neurological disorders
SI1200402T1 (sl) Substituirani 1,5-dihidropirol-2-on-derivati, ucinkoviti kot antagonisti NMDA-receptorja za tretiranje bolecinskih stanj
ZA200504565B (en) 1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20091113